Serving the company for over a decade, Mark A. Mintun, M.D., acts as the group vice president-neuroscience research and development and president of Avid Radiopharmaceuticals for Eli Lilly and Company. He is responsible for Lilly’s neuroscience R&D program, leading teams of researchers studying the pathology of neurodegenerative diseases, including Alzheimer’s, as a basis for developing treatments to target disease drivers. Mark had been the vice president of pain and neurodegeneration research and clinical development since January 2018.  In 2010, Mark joined Avid Radiopharmaceuticals, a wholly own...read more